Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668398 | 0.98 | CYP1A2 (0.52) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL14262605 | 0.93 | KDM5A (0.49) | CYP1A2KDM5APHF8KDM2AKDM4C | |
| SCHEMBL17297348 | 0.91 | KDM5A (0.51) | CYP1A2KDM5APHF8KDM2AKDM4C | |
| SCHEMBL8025386 | 0.91 | KDM5A (0.51) | CYP1A2KDM5APHF8KDM2AKDM4C | |
| SCHEMBL4990375 | 0.91 | KDM5A (0.50) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL10811442 | 0.91 | — | — | |
| SCHEMBL7909306 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL5274891 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL15177356 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL8814713 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375561-A | Method for flexibly producing cyclopentanone and cyclopentanol | 山东京博石油化工有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
| EP-1067118-B1 | Cyclopentylalkyl-nitriles and the use of odoriferous cyclopentylalkyl derivatives as fragrances | GIVAUDAN SA (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-6441052-B1 | ALKANOL, ALDEHYDE, AND KETONE CYCLOPENTA DERIVATIVES; FRAGRANCES | GIVAUDAN SA (CH) | 2002-08-27 | — | — | US | disclosed |
| US-20020086901-A1 | CYCLOPENTYLALKYL-NITRILES | GIVAUDAN SA, A SWITZERLAND CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6410000-B1 | PERFUME | GIVAUDAN SA (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6399811-B1 | ORGANOLEPTIC | GIVAUDAN SA (CH) | 2002-06-04 | — | — | US | disclosed |
| EP-1067118-A1 | Cyclopentylalkyl-nitriles and the use of odoriferous cyclopentylalkyl derivatives as fragrances | Givaudan SA (CH) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | CYP1A2 568/4885HPGD 866/4885KDM5A 567/4885 |
| US-20020086901-A1 | CYCLOPENTYLALKYL-NITRILES | CCRL2, CBR1, CNR1 | CYP1A2 433/4885HPGD 2283/4885KDM5A 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.